is question The really one. interesting designed, over-engineered. the first construct was a The way it was
itself, untranslated construct. These micro are micro of additional the are there the binding regulatory region in sites RNA. three an RNA sites in six down to So actual the binding plus construct
any in need sure be this appropriate truly Chief sure only that two, MECPX. of Sarah we to to partnership make able sites of to within ACE to be to frank, over issue kind one, But copies, we of overabundance an maybe order you of going because four these down really regulatory Now, are Sinnett our do in the express keep micro Steve built Scientific three not make of RNA Gray, in or MECPX the Adviser, range. targeting physiological level binding with
rats, we over is initial dose of number know the period, XEXX The given initial human in a Now, the studies in know there's fourfold dose. XEXX we've copies, all in both and NHPs month starting What the toxicology don't exact doses up that. that six three both over stuff, And we way three gave toxicology do dose, we the total from and vg. genome equivalent. a to
intrathecal copies overdosing sort adverse toxicological high see of to getting actually dose, of dose no the we gene initial know clinical with an we or, starting you well, numbers know of cells the that that And high. findings. so, fourfold minimal that – adverse And of there's
absolute humans, that in to not confidence the toxicology given below going the result studies, far overexpression. have going in question. is I that we level answered XEXX hope highest So is your into the which first the dose
kilos about time, this it's from second case, or into systemically, you The of i.e. a translatability very you question a dose children give the interesting. to vein, a dose adults per basis. adults to in from Most when on down drug children, vg
So, will old year a weigh generally six XX kilos. for example, boy
because as you're rates, therapy toddlerhood gene and delivered babies drug, grow at the that, the weight. that's XX if So, through that weighs, an different that and different don't to giving – weigh XEXX organs intrathecally thing into body drug all weighed the boy brain. grows who XX, dose you space. that obviously, the vg It's I multiply And he different you that the multiply is is kilos delivered limited so you XX fastest, know, XX, the kilos, XX year for very giving, other may on children girl, of in kilo, a almost by kilos, or the develop do an and larger per rest it's teenage adult XX a proportion old may a the the number translatability organ years, the biggest a CNS the their you're from
pretty issue and ages adults. And similar zero of really and a translatability CSF between an age, so, four child to brain of only years volume Once hits dose are the volume four. is the
same and volume. and down it's very both dependent or this, dose the a got brain age of been moderating ratio we done the the Below the of literature, the whether and of the looking every with child And done adult, age, kind of patient, modeling we've pediatric a so, we volume got and the of FDA other adult way give doing And after a regulators. CSF and and we've lot an we've about on four four, thoughtful dose. approach the And the they're animal an of of lot a age years we've doses. discussed at for the
But majority study who in the I enrolling agreement. they're very in And three over patients much So, be be say, I or think the it's to size four. probably of age, of three reaches three will will as year vast age the not likely the an going old, time because adult. the or four of reached or dose, change we're of the they've brain four years child size therefore, pediatric a by that a of
it's current the So, to to it's protocol be same be is starting the likely way – the pediatric total vg going XEXX as designed, dose.
Sorry, questions. there were too long answers. comprehensive your But hopefully answers I gave to you
